List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6203076/publications.pdf Version: 2024-02-01



FILEN WADNED

#	Article	IF	CITATIONS
1	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. British Journal of Cancer, 2022, 126, 302-309.	2.9	18
2	Couplelinks online intervention for young couples facing breast cancer: A randomised controlled trial. Psycho-Oncology, 2022, 31, 512-520.	1.0	11
3	Surgeon and Patient Reports of Fertility Preservation Referral and Uptake in a Prospective, Pan-Canadian Study of Young Women with Breast Cancer. Annals of Surgical Oncology, 2022, 29, 3022-3033.	0.7	4
4	ASO Author Reflections: Referring Young Breast Cancer Patients for Fertility Preservation: Significant Progress but Still Room for Improvement. Annals of Surgical Oncology, 2022, , 1.	0.7	0
5	Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. Clinical Cancer Research, 2022, 28, 2339-2348.	3.2	20
6	ASO Visual Abstract: Surgeon and Patient Reports of Fertility Preservation Referral and Uptake in a Prospective Pan-Canadian Study of Young Women with Breast Cancer. Annals of Surgical Oncology, 2022, 29, 3036-3037.	0.7	0
7	Risk factors for psychological morbidity and the protective role of coping self-efficacy in young women with breast cancer early in diagnosis: a national multicentre cohort study. Breast Cancer Research and Treatment, 2022, 194, 91-102.	1.1	8
8	Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2021, 186, 157-165.	1.1	12
9	Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature. Journal of Medical Radiation Sciences, 2021, 68, 96-102.	0.8	10
10	Abstract PS10-33: Analysis of factors associated with pathological complete response (pCR) in patients with HER2+ breast cancer receiving neoadjuvant chemotherapy. , 2021, , .		0
11	Patients' and Oncologists' Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative Review. Oncologist, 2021, 26, e1359-e1371.	1.9	16
12	Testing for clonal hematopoiesis of indeterminate potential in breast cancer survivors Journal of Clinical Oncology, 2021, 39, e24108-e24108.	0.8	0
13	Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study. Breast Cancer Research and Treatment, 2021, 189, 797-806.	1.1	5
14	Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. Npj Breast Cancer, 2021, 7, 99.	2.3	11
15	Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study. Breast, 2021, 58, 34-41.	0.9	1
16	Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Research and Treatment, 2021, 189, 689-699.	1.1	21
17	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. European Journal of Cancer, 2021, 155, 13-24.	1.3	7
18	Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. JAMA Surgery, 2021, 156, e213758.	2.2	18

#	Article	IF	CITATIONS
19	Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A <scp>Single-Center</scp> Retrospective Study. Oncologist, 2021, 26, e1951-e1961.	1.9	9
20	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast, 2021, 59, 327-338.	0.9	31
21	Clinical practice patterns for advanced breast cancer patients on CDK4/6 inhibitors receiving palliative radiation therapy Journal of Clinical Oncology, 2021, 39, 269-269.	0.8	3
22	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. Data in Brief, 2021, 38, 107354.	0.5	2
23	Reproductive concerns and fear of cancer recurrence: a qualitative study of women's experiences of the perinatal period after cancer. BMC Pregnancy and Childbirth, 2021, 21, 738.	0.9	4
24	Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program. Journal of the National Cancer Institute, 2020, 112, 136-144.	3.0	55
25	Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?. Clinical Breast Cancer, 2020, 20, e54-e64.	1.1	41
26	Feasibility and acceptability of iâ€Restoring Body Image after Cancer (iâ€ReBIC): A pilot trial for female cancer survivors. Psycho-Oncology, 2020, 29, 639-646.	1.0	7
27	Effect of a Knowledge-Translation Intervention on Breast Surgeons' Oncofertility Attitudes and Practices. Annals of Surgical Oncology, 2020, 27, 1645-1652.	0.7	6
28	Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. Journal of Clinical Oncology, 2020, 38, 725-733.	0.8	46
29	Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program. Cancers, 2020, 12, 3479.	1.7	13
30	Hereditary colorectal cancer screening: A 10-year longitudinal cohort study following an educational intervention. Preventive Medicine Reports, 2020, 20, 101189.	0.8	3
31	Update on fertility preservation for younger women with breast cancer. Cmaj, 2020, 192, E1003-E1009.	0.9	9
32	Re: "ABM Clinical Protocol #34: Breast Cancer and Breastfeeding―by Johnson HM, et al Breastfeeding Medicine, 2020, 15, 813-813.	0.8	0
33	Restoring body image after cancer (ReBIC): A group therapy intervention. Psycho-Oncology, 2020, 29, 671-680.	1.0	8
34	Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations. Human Reproduction, 2020, 35, 434-445.	0.4	17
35	Infant feeding among women with a history of breast cancer. Journal of Cancer Survivorship, 2020, 14, 356-362.	1.5	6
36	Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC) Journal of Clinical Oncology, 2020, 38, 1055-1055.	0.8	3

#	Article	lF	CITATIONS
37	Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer Journal of Clinical Oncology, 2020, 38, 514-514.	0.8	0
38	The "Begin Exploring Fertility Options, Risks and Expectations" (BEFORE) decision aid: development and alpha testing of a fertility tool for premenopausal breast cancer patients. BMC Medical Informatics and Decision Making, 2019, 19, 203.	1.5	20
39	Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC) Journal of Clinical Oncology, 2019, 37, 1041-1041.	0.8	7
40	Leeomic: A comprehensive proteomic analysis towards discovery of predictive patterns of protein expression to ribociclib sensitivity and resistance—A compLEEment-1 Canadian correlative sub-study Journal of Clinical Oncology, 2019, 37, TPS3170-TPS3170.	0.8	0
41	Diagnostic and treatment delays in young women with breast cancer Journal of Clinical Oncology, 2019, 37, 6575-6575.	0.8	0
42	Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H) Journal of Clinical Oncology, 2019, 37, 554-554.	0.8	0
43	Barriers to fertility preservation (FP) in a prospective pan-Canadian study of young women with breast cancer (YWBC) Journal of Clinical Oncology, 2019, 37, 136-136.	0.8	0
44	Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. Oncologist, 2018, 23, 768-775.	1.9	19
45	Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program. Molecular Genetics & Genomic Medicine, 2018, 6, 213-223.	0.6	9
46	RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. Journal of the National Cancer Institute, 2018, 110, 918-918.	3.0	2
47	Restoring Body Image After Cancer (ReBIC): Results of a Randomized Controlled Trial. Journal of Clinical Oncology, 2018, 36, 749-756.	0.8	46
48	Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer. Cancers, 2018, 10, 477.	1.7	36
49	Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer Journal of Clinical Oncology, 2018, 36, 533-533.	0.8	4
50	Will women with breast cancer (BC) be willing to take an adjuvant CDK4/6 inhibitor in addition to endocrine therapy (ET)?. Journal of Clinical Oncology, 2018, 36, e12566-e12566.	0.8	1
51	"What if I keep my breasts?" Extended follow-up of unaffected <i>BRCA</i> mutation carriers diagnosed with breast cancer (BC) in the Toronto magnetic resonance imaging (MRI) screening study Journal of Clinical Oncology, 2018, 36, 1523-1523.	0.8	1
52	The effect of surgery type on survival and recurrence in very young women with breast cancer. Journal of Surgical Oncology, 2017, 115, 122-130.	0.8	22
53	Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall health. Cmaj, 2017, 189, E268-E274.	0.9	67
54	MRI surveillance for women with dense breasts and a previous breast cancer and/or high risk lesion. Breast, 2017, 34, 77-82.	0.9	19

#	Article	IF	CITATIONS
55	Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. European Journal of Cancer, 2017, 85, 31-38.	1.3	32
56	Impact of fertility preservation by ovarian stimulation on breast cancer outcomes Journal of Clinical Oncology, 2017, 35, e21588-e21588.	0.8	1
57	Does a dedicated program for young breast cancer patients affect the likelihood of fertility preservation discussion and referral?. Breast, 2016, 27, 22-26.	0.9	29
58	A Rosier Picture for Young Women With Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2079-2081.	0.8	4
59	Oncofertility Knowledge, Attitudes, and Practices of Canadian Breast Surgeons. Annals of Surgical Oncology, 2016, 23, 3850-3859.	0.7	16
60	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Ca-A Cancer Journal for Clinicians, 2016, 66, 43-73.	157.7	497
61	Complete Response of Metastatic Androgen Receptor–Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature. Journal of Clinical Oncology, 2016, 34, e21-e24.	0.8	67
62	Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. British Journal of Cancer, 2016, 114, 631-637.	2.9	99
63	A Metric for Reducing False Positives in the Computer-Aided Detection of Breast Cancer from Dynamic Contrast-Enhanced Magnetic Resonance Imaging Based Screening Examinations of High-Risk Women. Journal of Digital Imaging, 2016, 29, 126-133.	1.6	2
64	Sexual functioning in breast cancer survivors experiencing body image disturbance. Psycho-Oncology, 2016, 25, 66-76.	1.0	109
65	Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer. Breast Journal, 2015, 21, 658-664.	0.4	10
66	Magnetic Resonance Imaging Improves Breast Screening Sensitivity in <i>BRCA</i> Mutation Carriers Age ≥ 50 Years: Evidence From an Individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 349-356.	0.8	72
67	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. Breast, 2015, 24, 201-207.	0.9	97
68	Couplelinks - an online intervention for young women with breast cancer and their male partners: study protocol for a randomized controlled trial. Trials, 2015, 16, 33.	0.7	24
69	Breast MRI as an Adjunct to Mammography for Breast Cancer Screening in High-Risk Patients: Retrospective Review. American Journal of Roentgenology, 2015, 204, 889-897.	1.0	49
70	The impact of a breast cancer diagnosis in young women on their relationship with their mothers. Breast, 2014, 23, 50-55.	0.9	15
71	Effectiveness of Screening With Annual Magnetic Resonance Imaging and Mammography: Results of the Initial Screen From the Ontario High Risk Breast Screening Program. Journal of Clinical Oncology, 2014, 32, 2224-2230.	0.8	106
72	Breast Surveillance of Patients with BRCA1 and BRCA2 Mutations. Current Breast Cancer Reports, 2013, 5, 255-261.	0.5	1

#	Article	lF	CITATIONS
73	Exploring the influence of genderâ€role socialization and objectified body consciousness on body image disturbance in breast cancer survivors. Psycho-Oncology, 2013, 22, 2177-2185.	1.0	54
74	Family history and breast cancer. Cmaj, 2012, 184, 1391-1391.	0.9	1
75	Differences in Natural History between Breast Cancers in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1458-1468.	1.1	79
76	Applying the 2011 Canadian guidelines for breast cancer screening in practice. Cmaj, 2012, 184, 1803-1807.	0.9	15
77	Experience of Young Women Diagnosed With Breast Cancer Who Undergo Fertility Preservation Consultation. Clinical Breast Cancer, 2012, 12, 127-132.	1.1	69
78	Genetic testing referral, uptake, and results in a program for women age 40 or younger with breast cancer Journal of Clinical Oncology, 2012, 30, 1542-1542.	0.8	0
79	Implementation of a population-based breast screening program for high-risk women in Ontario: The Ontario Breast Screening Program (OBSP) High-Risk Program Journal of Clinical Oncology, 2012, 30, e12034-e12034.	0.8	0
80	Variants of uncertain significance in BRCA testing: Impact on risk perception, worry, prevention, and counseling Journal of Clinical Oncology, 2012, 30, 1555-1555.	0.8	0
81	Breast-Cancer Screening. New England Journal of Medicine, 2011, 365, 1025-1032.	13.9	226
82	Improvement in DCIS Detection Rates by MRI Over Time in a High-Risk Breast Screening Study. Breast Journal, 2011, 17, 9-17.	0.4	43
83	Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer. Breast, 2011, 20, 254-258.	0.9	32
84	Psychological impact of recall on women with BRCA mutations undergoing MRI surveillance. Breast, 2011, 20, 424-430.	0.9	29
85	Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Research and Treatment, 2011, 125, 837-847.	1.1	97
86	Prospective Study of Breast Cancer Incidence in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation Under Surveillance With and Without Magnetic Resonance Imaging. Journal of Clinical Oncology, 2011, 29, 1664-1669.	0.8	248
87	The Attitudes of Women with BRCA1 and BRCA2 Mutations toward Clinical Breast Examinations and Breast Self-Examinations. Journal of Women's Health, 2009, 18, 1019-1024.	1.5	15
88	Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer. Annals of Internal Medicine, 2008, 148, 671.	2.0	463
89	Is Mammography Adequate for Screening Women with Inherited BRCA Mutations and Low Breast Density?. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 706-711.	1.1	32
90	The Role of Magnetic Resonance Imaging in Screening Women at High Risk of Breast Cancer. Topics in Magnetic Resonance Imaging, 2008, 19, 163-169.	0.7	31

#	Article	IF	CITATIONS
91	BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials. Clinical Cancer Research, 2007, 13, 7357-7362.	3.2	97
92	American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. Ca-A Cancer Journal for Clinicians, 2007, 57, 75-89.	157.7	2,234
93	Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer, 2005, 103, 1898-1905.	2.0	355
94	MRI surveillance for hereditary breast-cancer risk. Lancet, The, 2005, 365, 1747-1749.	6.3	40
95	Surveillance of <emph type="ITAL">BRCA1</emph> and <emph type="ITAL">BRCA2</emph> Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination. JAMA - Journal of the American Medical Association, 2004, 292, 1317.	3.8	1,033
96	Educating women about breast cancer. An intervention for women with a family history of breast cancer. Canadian Family Physician, 2003, 49, 56-63.	0.1	13
97	Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. Clinical Genetics, 2000, 57, 376-383.	1.0	42
98	Pilot study of an information aid for women with a family history of breast cancer. Health Expectations, 1999, 2, 118-128.	1.1	11
99	Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin: A case report. , 1996, 78, 2153-2156.		59
100	HIV-Associated Lymphoma of the Gastrointestinal Tract: The University of Toronto AIDS-Lymphoma Study Group Experience. Leukemia and Lymphoma, 1995, 16, 343-349.	0.6	12
101	Gastrointestinal Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1991, 4, 167-176.	0.6	5
102	Treatment Satisfaction With Couplelinks Online Intervention to Promote Dyadic Coping in Young Couples Affected by Breast Cancer. Frontiers in Psychology, 0, 13, .	1.1	4